Russian Heart Failure Journal 2010year Effect of standard drug therapy and its combination with CPAP-therapy (continuous positive airway pressure) on the disease flow in patients with chronic heart failure and breathing disorders during sleep


To access this material please log in or register

Register Authorize
2010/

Effect of standard drug therapy and its combination with CPAP-therapy (continuous positive airway pressure) on the disease flow in patients with chronic heart failure and breathing disorders during sleep

Belyavskiy E. A., Aksenova A. V., Baklanova N. A., Bolotova M. N., Galitsin P. V., Litvin A. Y., Kalinkin A. L., Mareev V. Y.

Keywords: apnea, hypopnea, desaturation, apnea index, hypopnea index, desaturation index, CHF

DOI: 10.18087/ rhfj.2010.3.1281

Topicality. Present few data shows that sleep disorders may worsen CHF flow and promote its progression. Objective. To study the effect of standard drug therapy and its combination with CPAP-therapy on CHF flow in patients with breathing disorders during sleep. Materials and methods. All 60 men with CHF I–IV FC NYHA, included into the study, received standard drug therapy for CHF. Patients were randomised into 2 groups: without apnea (n=16) and with sleep apnea (n=44). Patients, able to tolerate therapy with continuous positive airway pressure, formed CPAP-therapy group. The rest of patients were randomized into a group receiving diakarb and control group. At baseline and in 12 weeks of treatment patients underwent general clinical examination, polysomnography, 6 min walking test, echocardiography, 24 hour ECG and blood preassure monitoring, quality of life assessment, daily urine catecholamines excretion. Results. Active drug therapy improves quality of life and CHF flow, but it does not eliminate obstructive breathing disorders during sleep. Diakarb prescribing did not influence on severity of obstructive sleep apnea. CPAP-therapy decreased apnea-hypopnea index and improved erectile function in men with CHF. However, this method did not improve CHF flow.
  1. Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения сердечной недостаточности. – М.: Materia Medica, 2000. – 266с.
  2. Wolk R, Somers VK. Cardiovascular consequences of obstructive sleep apnea. Clin Chest Med. 2003;24 (2):195–205.
  3. Bradley TD, Hall MJ, Ando S, Floras JS. Hemodynamic effects of simulated obstructive apneas in humans with and without heart failure. Chest. 2001;119 (6):1827–1835.
  4. Вейн А. М., Елигулашвили Т. С., Полуэктов М. Г. Синдром апноэ во сне и другие расстройства дыхания, связанные со сном: клиника, диагностика, лечение М. "Эйдос Медиа" – 2002–310 c.
  5. Bradley TD, Floras JS. Sleep apnea and heart failure: Part I: obstructive sleep apnea. Circulation. 2003;107 (12):1671–1678.
  6. Guilleminault C, Eldridge F, Dement WC. Insomnia with sleep apnea: a new syndrome. Science. 1973;181 (102):856–858.
  7. Sullivan CE, Issa FG, Berthon-Jones M, Eves L. Reversal of obstructive steep apnoea by continuous positive airways pressure applied through the nares. Lancet. 1981;1 (8225):862–865.
  8. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol. 2003;41 (9):1429–1437.
  9. Young T, Finn L, Peppard PE et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep. 2008;31 (8):1067–1068.
  10. Nieto FJ, Young TB, Lind BK et al. Association of sleep-disordered brea­thing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000;283 (14):1829–1836.
  11. Haas DC, Foster GL, Nieto FJ et al. Age-dependent associations between sleep-disordered breathing and hypertension: importance of discriminating between systolic / diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study. Circulation. 2005;111 (5):614–621.
  12. Sin DD, Fitzgerald F, Parker JD et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med. 1999;160 (4):1101–1106.
  13. Javaheri S, Parker TJ, Liming JD et al. Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation. 1998;97 (21):2154–2159.
  14. Ancoli-Israel S, Kripke DF, Klauber MR et al. Sleep-disordered breathing in community-dwelling elderly. Sleep. 1991;14 (6):486–495.
  15. White D. P. Central sleep apnea. Principles and Practice of Sleep Medicine: 2‑nd ed. Philadelphia: Harcourt Brace & Company. – 1994 – p. 630–641.
  16. Елигулашвили Т. С. Неврологические аспекты синдрома апноэ во сне: Клинико-физиологическое исследование. Дисс… д-ра мед. наук. – М. –1998.
  17. Schultz R, Mahmoudi S, Hattar K et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med. 2000;162 (2 Pt 1):566–570.
  18. Ip MS, Lam B, Chan LY et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med. 2000;162 (6):2166–2171.
  19. Lanfranchi PA, Braghiroli A, Bosimini E et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation. 1999;99 (11):1435–1440.
  20. Sin DD, Logan AG, Fitzgerald FS et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation. 2000;102 (1):61–66.
  21. Калинкин А. Л. Полисомнографическое исследование. Функциональная диагностика. 2004;2:61–65.
  22. Wang H, Parker JD, Newton GE et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol. 2007;49 (15):1625–1631.
  23. Goodfriend TL, Calhound DA. Resistant hypertension, obesity, sleep apnea and aldosterone: theory and therapy. Hypertension. 2004;43 (3):518–524.
  24. Guilleminault C, Dement WC. Sleep apnea syndromes and related sleep disorders, in Sleep Disorders: Diagnosis and Treatment, edited by Williams RL, Karacan I, New York, Wiley, 1978, pp. 9–28.
  25. Bliwise D.,Feldman D.,Bliwise N. et al. Risk factors for sleep-disordered breathing in heterogenous heriatric populations. J Am Geriatr Soc. 1987;35 (2):132–141.
  26. Silverberg DS, Oksenberg A, Iaina A. Sleep-related breathing disorders as a major cause of essential hypertension: fact or fiction? Curr Opin Nephrol Hypertens. 1998;7 (4):353–357.
  27. Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? Curr Hypertens Rep. 2001;3 (3):209–215.
  28. Hla KM, Young TB, Bidwell T et al. Sleep apnea and hypertension. A population-based study. Ann Intern Med. 1994;120 (5):382–388.
  29. Shepard JW Jr. Hypertension, cardiac arrhythmias, myocardial infarction and stroke in relation to obstructive sleep apnea. Clin Chest Med. 1992;13 (3):437–458.
  30. Levy D, Larson M, Vasan R et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275 (20):1557–1562.
  31. Brooks D, Horner RL, Kozar LF et al. Obstructive sleep apnea as a cause of systemic hypertension: evidence from a canine model. J Clin Invest. 1997;99 (1):106–109.
  32. Brinker JA, Weiss JL, Lappé DL et al. Leftward septal displacement during right ventricular loading in man. Circulation. 1980;61 (3):626–633.
  33. Fletcher EC, Proctor M, Yu J et al. Pulmonary edema develops after recurrent obstructive apneas. Am J Respir Crit Care Med. 1999;160 (5 Pt 1):1688–1696.
  34. Horner RL, Brooks D, Kozar LF et al. Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. J Appl Physiol. 1995;79 (1):151–162.
  35. Dimsdale JE, Coy T, Ziegler MG et al. The effect of sleep apnea on plasma and urinary catecholamines. Sleep. 1995;18 (5):377–381.
  36. Phillips BG, Narkiewicz K, Pesek CA et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens. 1999;17 (1):61–66.
  37. Fletcher EC, Lesske J, Culman J et al. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension. 1992;20 (5):612–619.
  38. Narkiewicz K, Kato M, Phillips BG et al. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation. 1999;100 (23):2332–2335.
  39. Narkiewicz K, van de Borne PJ, Cooley RL et al. Sympathetic activity in obese subjects with and without obstructive sleep apnea Circulation. 1998;98 (8):772–776.
  40. Carlson JT, Hedner J, Elam M et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest. 1993;103 (6):1763–1768.
  41. Voogel AJ, van Steenwijk RP, Karemaker JM, van Montfrans GA. Effects of treatment of obstructive sleep apnea on circadian hemodynamics. J Auton Nerv Syst. 1999;77 (2-3):177–183.
  42. Xie A, Skatrud JB, Puleo DS, Morgan BJ. Exposure to hypoxia produces long-lasting sympathetic activation in humans. J Appl Physiol. 2001;91 (4):1555–1562.
  43. García-Río F, Racionero MA, Pino JM et al. Sleep apnea and hypertension. Chest. 2000;117 (5):1417–1425.
  44. Carlson JT, Hedner J, Elam M et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest. 1993;103 (6):1763–1768.
  45. Fletcher EC, Miller J, Schaaf JW, Fletcher JG. Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension. Sleep. 1987;10 (1):35–44.
  46. Biesold D, Kurosawa M, Sato A, Trzebski A. Hypoxia and hypercapnia increase sympathoadrenal medullary functions in anesthetized, artificially ventilated rats. Jpn J Physiol. 1989;39 (4):511–522.
  47. Buerk DG, Lahiri S, Chugh D et al. Electrochemical detection of rapid DA release kinetics during hypoxia in perfused-superperfused cat CB. J Appl Physiol. 1995;78 (3):830–837.
  48. Donnelly DF. Electrochemical detection of catecholamine release from rat carotid body in vitro. J Appl Physiol. 1993;74 (5):2330–2337.
  49. Crabb JE, Pingleton SK, Gollub S et al. Sleep disordered breathing in decom­pensated and compensated congestive heart failure. Am Rev Respir Dis. 1985;131:104.
  50. Köhnlein T, Welte T. Does beta-blocker treatment influence central sleep apnoea? Respir Med. 2007;101 (4):850–853.
  51. DeBacker WA, Verbraecken J, Willemen M et al. Central apnea index decreases after prolonged treatment with acetazolamide. Am J Respir Crit Care Med. 1995;151 (1):87–91.
  52. Javahery S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study.. Am J Respir Crit Care Med. 2006;173 (2):234–237.
  53. Tojima H, Kunitomo F, Kimura K et al. Effects of acetazolamide in patients with sleep apnoea syndrome. Thorax. 1988;43 (2):113–119.
  54. Kaneko Y, Floras JS, Usui K et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med. 2003;348 (13):1233–1241.
  55. Cooper BG, White JES, Ashworth A et al. Hormonal and metabolic profiles in subjects with obstructive sleep apnea syndrome and the acute effects of nasal continuous positive airway pressure (CPAP) treatment. Sleep. 1995;18 (3):172–179.
  56. Mansfield DR, Gollogly NC, Kaye DM et al. Controlled trial of conti­nuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med. 2004;169 (3) :361–366.
Belyavskiy E. A., Aksenova A. V., Baklanova N. A. et al. Effect of standard drug therapy and its combination with CPAP-therapy (continuous positive airway pressure) on the disease flow in patients with chronic heart failure and breathing disorders during sleep. Russian Heart Failure Journal. 2010;11(3):161-167.

To access this material please log in or register

Register Authorize
Ru En